DGAP-News: Apricus Biosciences Announces Second Quarter 2011 Financial Results Conference Call

(firmenpresse) - Apricus Biosciences, Inc.

11.08.2011 22:30
---------------------------------------------------------------------------

Conference Call/Webcast to be held Monday, August 15, 2011 at 10:00 a.m. ET

SAN DIEGO, 2011-08-11 22:30 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
management will hold a conference call to discuss its second quarter 2011
financial results and ongoing corporate activities on Monday, August 15, 2011
at 10:00 a.m. ET. The Company will file its Form 10-Q for the quarter ended
June 30, 2011 by the opening of business on Monday, August 15, 2011.

The call can be accessed in the U.S. by dialing 877-407-0778 and outside of the
U.S. by dialing 201-689-8565 and asking the conference operator for the Apricus
Bio Conference Call. The teleconference replay will be available for one week
by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing
201-612-7415. Replay passcodes 286 and 377454 are both required for playback.
The conference call will also be Webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=165624. The Webcast replay
will be available for three months.

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes. Revenues and growth are driven from
out-licensing of this technology for the development and commercialization of
such compounds to pharmaceutical and biotechnology companies worldwide. In
addition, the Company is seeking to monetize its existing product pipeline,
including its first product, Vitaros(r), approved in Canada for the treatment of
erectile dysfunction, which is currently expected to be available on the


Canadian market in 2011, as well as compounds in development from pre-clinical
through Phase III, currently focused on sexual dysfunction, oncology,
dermatology, autoimmune, pain, anti-infectives, diabetes and cosmeceuticals
among others.

For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiary, please visit www.nexmedusa.com. You can also
find out more about the company by visiting http://twitter.com/apricusbio and
http://facebook.com/apricusbio.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop products and
product candidates, to have its products and product candidates approved by
relevant regulatory authorities, to successfully commercialize such products
and product candidates and to achieve its other development, commercialization
and financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without
charge from the Company.


CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations&Corporate Development
Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com

Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX



11.08.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Apricus Biosciences, Inc.


United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
Datum: 11.08.2011 - 22:30 Uhr
Sprache: Deutsch
News-ID 460572
Anzahl Zeichen: 5465

Kontakt-Informationen:

Kategorie:

Wirtschaft (allg.)

Diese Pressemitteilung wurde bisher 294 mal aufgerufen.

DGAP-News: Apricus Biosciences vor Ubernahme des umsatzstarksten Vertriebs- und Marketingunternehmens fur Medikamente in Frankreich ...
Apricus Biosciences, Inc. 21.06.2012 22:44 --------------------------------------------------------------------------- Ubernahme von Finesco-Scomedica ermoglicht Apricus Bio die direkte Einfuhrung von Vitaros(R) und anderen Produkten in Frankreich, dem zweitgrossten Markt fur

DGAP-News: Apricus Biosciences Announces Appointment of Paul V. Maier to Its Board of Directors ...
Apricus Biosciences, Inc. 04.06.2012 15:39 --------------------------------------------------------------------------- SAN DIEGO, 2012-06-04 15:39 CEST (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) (www.apricusbio.com) today announced that Paul V. Maier, Ch

DGAP-News: Apricus Biosciences Strengthens Vitaros(R) and Nexact(R) Patent Estate With Two New Patent Allowances ...
Apricus Biosciences, Inc. 25.05.2012 19:20 --------------------------------------------------------------------------- SAN DIEGO, 2012-05-25 19:20 CEST (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI) (http://www.apricusbio.com), ann

Weitere Mitteilungen von Apricus Biosciences, Inc.

Neuer memento-Service: Bitte um „Kranzspende“ auf der Trauerkarte ...
Statt eines Kranzes eine Spende für SOS-Kinderdorf. Wer als Hinterbliebener über das Online-Portal www.memento-online.de Trauerkarten, Trauerbriefe oder Erinnerungsbilder bestellt und an Verwandte, Freunde und Bekannte des Verstorbenen verschicken will, der kann mit einem entsprechenden Eindruck a

DGAP-News: GBC Investment im Fokus: SÜSS MicroTec AG - Halbjahreszahlen voll im Plan - Aktie deutlich unterbewertet ...
DGAP-News: GBC AG / Schlagwort(e): Research Update/Halbjahresergebnis GBC Investment im Fokus: SÜSS MicroTec AG - Halbjahreszahlen voll im Plan - Aktie deutlich unterbewertet 11.08.2011 / 19:00 --------------------------------------------------------------------- GBC Investment im Fokus: SÜSS M

DGAP-News: Francotyp-Postalia Holding AG: Verhandlungenüber Interessenausgleich gescheitert ...
DGAP-News: Francotyp-Postalia Holding AG / Schlagwort(e): Unternehmensrestrukturierung/Unternehmensrestrukturierung Francotyp-Postalia Holding AG: Verhandlungenüber Interessenausgleich gescheitert 11.08.2011 / 18:00 --------------------------------------------------------------------- Verhandlun

DGAP-News: CR Capital Real Estate AG: Endgültige Jahreszahlen 2010 bestätigen vorläufiges Ergebnis ...
DGAP-News: CR Capital Real Estate AG / Schlagwort(e): Jahresergebnis CR Capital Real Estate AG: Endgültige Jahreszahlen 2010 bestätigen vorläufiges Ergebnis 11.08.2011 / 17:47 --------------------------------------------------------------------- CR Capital Real Estate AG: Endgültige Jahreszah